27350 Dupilumab improves Eczema Area and Severity Index regional scores across all anatomical regions in children aged 6–11 years with severe atopic dermatitis (AD)

Abstract

Background: AD, a chronic inflammatory skin disease, can affect different parts of the body. Dupilumab inhibits interleukin (IL)-4 and IL-13 signaling and is approved for treating multiple type 2 inflammatory diseases, including AD. We evaluated improvement in AD signs, using Eczema Area and Severity Index (EASI) Regional Scores, across anatomic regions in children with severe AD, treated with FDA-approved dupilumab doses.